That is roughly 45-50 pounds for someone weighing 220 pounds
degludec assoc with: Liver fat content (LFC) 18-28% Both in either HbA1c or weight assoc with Both the visceral & subcutaneous abdominal fat equally ALT 4-22% AST 10-19% SURPASS-3 MRI trial (3/3) tirzepatide (particularly 10-15mg doses) looks to be possible treatments for #NAFLD #NASH, as well as #type2diabetes ongoing liver outcome RCT with liver biopsy clinicaltrials.gov/ct2/show/NCT04 SURPASS-3 CGM (1/2) another sub-study of SURPASS-3 (n=243) Dexcom G6 CGM used 1ry outcome - Time within Tight Target range 3.9-7.8 mmol/mol (71-140 mg/dL) at 24 + 52w % time within standard target range 3.9-10 mmol/mol (71-180 mg/dL) at 52w Presented by @TBattelino SURPASS - CGM (2/2) tirzepatide treatment assoc with: Marked in Tight TIR compared to ins
Constipation indicates that GLP-1 is slowing your digestive system, which is part of its appetite-suppressing mechanism, but it is not a requirement for weight loss success
HUBERMAN: As a consequence, all of the things that growth hormone does like encouraging higher metabolism, fat loss, the growth of muscle tissue, et cetera, is dramatically reduced as we go from 30 to 40 to 50 and on and on
It is always best to err on the side of caution and consult a doctor in these life stages
Insulin GLP-1 RA Pen References: Pyrls, pyrls.com (Login required) Accessed 12/04/2025
